APYX Valuation
Apyx Medical Corp
$
2.090
- Overview
- Forecast
- Valuation
- Earnings
APYX Relative Valuation
APYX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, APYX is overvalued; if below, it's undervalued.
Historical Valuation
Apyx Medical Corp (APYX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.44 is considered Undervalued compared with the five-year average of -10.42. The fair price of Apyx Medical Corp (APYX) is between 2.09 to 8.48 according to relative valuation methord. Compared to the current price of 2.06 USD , Apyx Medical Corp is Undervalued By 1.26%.
Relative Value
Fair Zone
2.09-8.48
Current Price：2.06
1.26%
Undervalued
-5.42
PE
1Y
3Y
5Y
Trailing
Forward
-11.45
EV/EBITDA
Apyx Medical Corp. (APYX) has a current EV/EBITDA of -11.45. The 5-year average EV/EBITDA is -15.11. The thresholds are as follows: Strongly Undervalued below -36.50, Undervalued between -36.50 and -25.81, Fairly Valued between -4.41 and -25.81, Overvalued between -4.41 and 6.29, and Strongly Overvalued above 6.29. The current Forward EV/EBITDA of -11.45 falls within the Historic Trend Line -Fairly Valued range.
-7.32
EV/EBIT
Apyx Medical Corp. (APYX) has a current EV/EBIT of -7.32. The 5-year average EV/EBIT is -9.65. The thresholds are as follows: Strongly Undervalued below -22.91, Undervalued between -22.91 and -16.28, Fairly Valued between -3.03 and -16.28, Overvalued between -3.03 and 3.60, and Strongly Overvalued above 3.60. The current Forward EV/EBIT of -7.32 falls within the Historic Trend Line -Fairly Valued range.
1.49
PS
Apyx Medical Corp. (APYX) has a current PS of 1.49. The 5-year average PS is 3.67. The thresholds are as follows: Strongly Undervalued below -1.92, Undervalued between -1.92 and 0.87, Fairly Valued between 6.46 and 0.87, Overvalued between 6.46 and 9.26, and Strongly Overvalued above 9.26. The current Forward PS of 1.49 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Apyx Medical Corp. (APYX) has a current P/OCF of 0.00. The 5-year average P/OCF is -6.39. The thresholds are as follows: Strongly Undervalued below -37.33, Undervalued between -37.33 and -21.86, Fairly Valued between 9.08 and -21.86, Overvalued between 9.08 and 24.55, and Strongly Overvalued above 24.55. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-6.29
P/FCF
Apyx Medical Corp. (APYX) has a current P/FCF of -6.29. The 5-year average P/FCF is -10.85. The thresholds are as follows: Strongly Undervalued below -30.86, Undervalued between -30.86 and -20.86, Fairly Valued between -0.84 and -20.86, Overvalued between -0.84 and 9.17, and Strongly Overvalued above 9.17. The current Forward P/FCF of -6.29 falls within the Historic Trend Line -Fairly Valued range.
Apyx Medical Corp (APYX) has a current Price-to-Book (P/B) ratio of 10.58. Compared to its 3-year average P/B ratio of 3.83 , the current P/B ratio is approximately 176.26% higher. Relative to its 5-year average P/B ratio of 4.52, the current P/B ratio is about 134.14% higher. Apyx Medical Corp (APYX) has a Forward Free Cash Flow (FCF) yield of approximately -13.46%. Compared to its 3-year average FCF yield of -18.90%, the current FCF yield is approximately -28.78% lower. Relative to its 5-year average FCF yield of -13.43% , the current FCF yield is about 0.21% lower.
10.73
P/B
Median3y
3.83
Median5y
4.52
-13.06
FCF Yield
Median3y
-18.90
Median5y
-13.43
Competitors Valuation Multiple
The average P/S ratio for APYX's competitors is 3.44, providing a benchmark for relative valuation. Apyx Medical Corp Corp (APYX) exhibits a P/S ratio of 1.49, which is -56.71% above the industry average. Given its robust revenue growth of -6.39%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of APYX increased by 57.14% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.27 to -4.61.
The secondary factor is the Revenue Growth, contributed -6.39%to the performance.
Overall, the performance of APYX in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Apyx Medical Corp (APYX) currently overvalued or undervalued?
Apyx Medical Corp (APYX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.44 is considered Undervalued compared with the five-year average of -10.42. The fair price of Apyx Medical Corp (APYX) is between 2.09 to 8.48 according to relative valuation methord. Compared to the current price of 2.06 USD , Apyx Medical Corp is Undervalued By 1.26% .
What is Apyx Medical Corp (APYX) fair value?
How does APYX's valuation metrics compare to the industry average?
What is the current P/B ratio for Apyx Medical Corp (APYX) as of Aug 23 2025?
What is the current FCF Yield for Apyx Medical Corp (APYX) as of Aug 23 2025?
What is the current Forward P/E ratio for Apyx Medical Corp (APYX) as of Aug 23 2025?